Business
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2024 and provide business highlights. Conference Call
About this update from Bioatla, Inc.
[{"type":"image","alt":"BioAtla, Inc.","displaySize":"","headline":null,"caption":"BioAtla, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":164,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/add243e63c7c504df7517ccebf39d348"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z8G3hxIezptosVzATIpKBQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTk2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/add243e63c7c504df7517ccebf39d348","width":164,"height":75}},"lazy":false},{"type":"text","content":"SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2024 and provide business highlights.","length":483,"tagName":"p"},{"type":"text","content":"Conference Call and Webcast Information Date: Thursday, March 27, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla Fourth Quarter and Full-Year 2024 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)Conference ID: BIOATLA","length":317,"tagName":"p"},{"type":"text","content":"The press release with the financial results will be accessible prior to the conference call through “News Releases” in the News & Events section of the company’s website. A replay of the call will also be available through “Events & Presentations” in the Investors section of the company’s website.","length":307,"tagName":"p"},{"type":"text","content":"About BioAtla®, Inc. BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturin...